Antisense Oligonucleotides: Rewriting the Future of Rare Inherited Genetic Diseases
Key Insights
Antisense oligonucleotides (ASOs) target messenger RNA (search) to alter how genetic information is processed before a harmful protein is made, offering a flexible therapeutic approach for rare inherited diseases.
A single gene may be linked to one condition, but many different mutations within that gene can produce the same disease, complicating treatment strategies that ASOs are uniquely positioned to address.
Design principles established for one ASO mutation can help guide development for other variants in the same gene, accelerating the path toward personalized therapies.
Rare genetic diseases, while individually uncommon, collectively affect millions of individuals worldwide. These conditions arise from inherited or new genetic changes, and for the families they touch, the experience is both isolating and devastating. Now, researchers at St. Jude Children's Research Hospital are advancing a therapeutic strategy that targets disease at the level of messenger RNA (search) (mRNA), offering new hope where conventional approaches have fallen short.
The approach centers on antisense oligonucleotides (ASOs)—short strands of nucleotides designed to be complementary to specific mRNA sequences. By binding to their target, ASOs alter how mRNA is processed, either removing the disease-causing transcript entirely to prevent production of a mutated protein, or compensating for the mutation to yield a partially or fully corrected protein.
The Challenge of Mutation Diversity
A central challenge in precision medicine is that a single gene may be linked to one condition, yet many different mutations within that gene can produce the same disease, often with a wide range of severities and clinical outlooks. This means each instance may result in a similar pathogenic impact but is different enough to require an individualized approach. Such complexity can make clinical investigation more difficult and limit available treatment strategies.
ASOs offer a promising way to address this problem. By targeting RNA rather than DNA, ASOs create a more adaptable framework for addressing disease-causing variants. The mRNA carries the same sequence as the coding, or "sense," strand of the gene—including the disease-causing error—and is subsequently translated into a disease-causing mutated protein or can result in a deficiency of a necessary protein. ASOs intervene at this intermediate step, before a harmful protein is ever made.
Carrying Knowledge Forward
One of the most significant advantages of the ASO platform is the transferability of design principles. Knowledge gained from designing an ASO for one mutation can help guide similar approaches for patients with a different mutation within the same gene. This can reduce the amount of time needed to clear regulatory hurdles and make the road to personalized care for rare inherited diseases fully realizable.
As of this year, only 14 ASOs have been approved by the Food and Drug Administration for the treatment of a variety of diseases. St. Jude is leading the design and use of ASOs to address rare inherited pediatric diseases, where the need for innovative therapeutic strategies is particularly acute.
A Future Rooted in Genetic Understanding
As scientific understanding of the origins of genetic diseases expands, so too does the ability to treat them with ASOs. These therapies hold the promise to treat not just rare inherited diseases, but many diseases rooted in genetics. What was once a life-altering fate written in genetic code can now be rewritten, restoring hope once thought out of reach for thousands of children with catastrophic genetic diseases.